Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab in Combination With Apatinib in in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma: a Phase Ib/II, Multicentre, Open-label, Single-arm Trial

NCT04476459 is registered in ClinicalTrials.gov with Huiqiang Huang as lead sponsor.

NCT NCT04476459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04476459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab in Combination With Apatinib in in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma: a Phase Ib/II, Multicentre, Open-label, Single-arm Trial
Lead sponsor
Huiqiang Huang
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 23, 2020
Completion date
August 1, 2023
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive anaplastic large cell lymphoma, diffuse large b cell lymphoma, ebv-positive dlbcl, nos, follicular lymphoma grade iiib, high-grade b-cell lymphoma, transformed lymphoma